When was Apricell Biotechnology founded?

Apricell Biotechnology was founded in 2021.

Where is Apricell Biotechnology located?

Apricell Biotechnology is headquartered in Victoria, Canada.

How many employees does Apricell Biotechnology have?

As of Jul 01, 2024, the latest employee count at Apricell Biotechnology is 2.

Is Apricell Biotechnology a funded company?

Apricell Biotechnology is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Apricell Biotechnology rank among its competitors?

Apricell Biotechnology ranks 516th amongst 468 active competitors, of which 158 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Caris Life Sciences, which secured $168M in Apr, 2025.

Who are the top competitors of Apricell Biotechnology?

Apricell Biotechnology's top competitors include Human Longevity, Juno Therapeutics and Caris Life Sciences. Among them, Caris Life Sciences secured the most recent funding round in April, 2025.

Apricell Biotechnology - 2026 Company Profile & Competitors

Apricell Biotechnology is an unfunded company based in Victoria (Canada), founded in 2021. It operates as a Developer of drug discovery and precision therapy platform for oncology. Apricell Biotechnology has not raised any funding yet. The company has 468 active competitors, including 158 funded and 95 that have exited. Its top competitors include companies like Human Longevity, Juno Therapeutics and Caris Life Sciences.

Company Details

Developer of drug discovery and precision therapy platform for oncology. The company has developed Tumoroid-on-a-chip technology which enables to deliver 3D cell-culture and in-silico models for individualized cancer therapy. Also provides an anti-cancer drug screening platform for individuals by using the apricell biochip platform.

Key Metrics

Founded Year

2021

Location

Victoria, Canada

Stage

Unfunded

Ranked

516^th among 624 competitors

Employee Count

2 as on Jul 01, 2024

Similar Companies

Human Longevity & 555 more

View Apricell Biotechnology's full profile

Apricell Biotechnology has not raised any funding rounds yet.

Apricell Biotechnology's employee count trend

Apricell Biotechnology has 2 employees as of Jul 24. Here is Apricell Biotechnology's employee count trend over the years:

Employee count trend for Apricell Biotechnology

Uncover Apricell Biotechnology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Apricell Biotechnology include Human Longevity, Juno Therapeutics and Caris Life Sciences. Here is the list of Top 10 competitors of Apricell Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Human Longevity 2013, San Diego (United States), Series B	Provider of precision medicine, preventative health assessments, and longevity care	$409M	Celgene, General Electric & 20 others	76/100
2nd	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
3rd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	74/100
4th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Advent Life Sciences, 4Bio Capital & 11 others	70/100
5th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 9 others	70/100
6th	Castle Biosciences 2008, Friendswood (United States), Public	Provider of diagnostic devices for treating cancer	$62M	Industry Ventures, Health Quest Capital & 9 others	70/100
7th	Personalis 2011, Menlo Park (United States), Public	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 4 others	69/100
8th	Congenica 2013, Cambridge (United Kingdom), Acquired	Provider of a platform for clinical genome analytics for treating patients with genetic diseases	$81.9M	IDO Investments, Parkwalk & 39 others	68/100
9th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
10th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	66/100
516th	Apricell Biotechnology 2021, Victoria (Canada), Unfunded	Developer of drug discovery and precision therapy platform for oncology	-	-	16/100